Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

01.12.2016 | original report

ASCO update 2016: colorectal cancer

verfasst von: Wolfgang Eisterer

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Summary

At this year’s annual meeting of the American Society of Clinical Oncology, held during 3–7 June 2016 in Chicago, USA, investigators discussed the latest findings in colorectal cancer research. The main topics were immune checkpoint inhibition therapy in colorectal cancer and the prognostic and predictive influence of sidedness in the primary tumor location.
Vorheriger Artikel ASCO update: gastric cancer
Nächster Artikel Extravasation emergencies: state-of-the-art management and progress in clinical research
Literatur
1.
Venook AP, Niedzwiecki D, Innocenti F, Fruth B, Greene C, O’Neil J, Shaw JE, Atkins JN, Horvath LE, Polite BN, Meyerhardt JA, O’Reilly EM, Goldberg RM, Hochster HS, Blanke CD, Schilsky RL, Mayer RJ, Bertagnolli MM, Lenz H‑J. Impact of primary (1º) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): analysis of CALGB/SWOG 80405 (Alliance). J Clin Oncol. 2016;34(suppl):abstr 3504.CrossRef
2.
Venook AP, Niedzwiecki D, Lenz H‑J, Innocenti F, Mahoney MR, O’Neil BH, Shaw JE, Polite BN, Hochster HS, Atkins JN, Goldberg RM, Mayer RJ, Schilsky RL, Bertagnolli MM, Blanke CD. CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol. 2014;32(suppl):abstr LBA3.CrossRef
3.
Heinemann V, Modest DP, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran S‑E, Heintges T, Lerchenmuller CA, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Held S, Giessen CA, Jung A, Kirchner T, Stintzing S. Gender and tumor location as predictors for efficacy: Influence on endpoints in first-line treatment with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK 0306 (FIRE3) trial. J Clin Oncol. 2014;32(suppl):abstr 3600.CrossRef
4.
Tie J, Wang Y, Tomasetti C, Li L, Springer S, Kinde I, Wong R, Kosmider S, Tran B, Desai T, Hayes TM, Haydon AM, Yip D, Christie M, Strausberg R, Diaz LA, Papadopoulos N, Kinzler KW, Vogelstein B, Gibbs P. The potential of circulating tumor DNA (ctDNA) to reshape the design of clinical trials testing adjuvant therapy in patients with early stage cancers. J Clin Oncol. 2016;34(suppl):abstr 3511.CrossRef
5.
Overman MJ, Kopetz S, McDermott RS, Leach J, Lonardi S, Lenz H‑J, Morse MA, Desai J, Hill A, Axelson MD, Moss RA, Lin C‑S, Goldberg M, Andre T. Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results. J Clin Oncol. 2016;34(suppl):abstr 3501.CrossRef
6.
Bendell JC, Kim TW, Goh BC, Wallin J, Oh D‑Y, Han S‑W, Lee CB, Hellmann MD, Desai J, Lewin JH, Solomon BJ, Chow LQM, Miller WH, Gainor JF, Flaherty K, Infante JR, Das-Thakur M, Foster P, Cha E, Bang Y‑J. Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC). J Clin Oncol. 2016;34(suppl):abstr 3502.CrossRef
7.
Le DT, Uram JN, Wang H, Bartlett B, kemberling H, Eyring A, Azad NS, Laheru D, Donehower RC, Crocenzi TS, Goldberg RM, Fisher GA, Lee JJ, Greten TF, Koshiji M, Kang SMP, Anders RA, Eshleman JR, Vogelstein B, Diaz LA. Programmed death-1 blockade in mismatch repair deficient colorectal cancer. J Clin Oncol. 2016;34(suppl):abstr 103.CrossRef
8.
Raghav RPS, Overman MJ, Yu R, Meric-Bernstam F, Menter D, Kee BK, Muranyi A, Singh S, Routbort M, Chen K, Shaw KR, Shannmugam K, Maru DM, Fakih M, Kopetz S. HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer. J Clin Oncol. 2016;34(suppl):abstr 3517.CrossRef
9.
Siena S, Sartore-Bianchi A, Lonardi S, Trusolino L, Martino C, Bencardino K, Leone F, Zagonel V, Valtorta E, Torri V, Siravegna G, Amatu A, Bonazzina EF, Rusconi F, Ghezzi S, Ciardiello F, Veronese S, Comoglio PM, Bardelli A, Marsoni S. Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial. J Clin Oncol. 2015;33(suppl):abstr 3508.CrossRef
Metadaten
Titel
ASCO update 2016: colorectal cancer
verfasst von
Wolfgang Eisterer
Publikationsdatum
01.12.2016
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 4/2016
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-016-0298-9

Weitere Artikel der Ausgabe 4/2016

ASCO update 2016

  • editorial

Recommendations of the Austrian Working Group on Pulmonary Pathology and Oncology for predictive molecular and immunohistochemical testing in non-small cell lung cancer

  • special report

Molecular pathogenesis of chronic myeloid leukemia

  • short review

Molecular pathogenesis of chronic myelomonocytic leukemia

  • short review

ASCO update: gastric cancer

  • short review

PD-L1 testing, fit for routine evaluation? From a pathologist’s point of view

  • Open Access
  • short review